One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations
Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022
The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. One critical finding was an increased risk of
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: IFM_05-May 2022